バクスター インターナショナルに関するコメント

$Direxion Daily S&P Biotech Bear 3x Shares ETF (LABD.US)$ Baxter expands portfolio with new injectable products in U.S.

Given Baxter International's low P/S ratio and inferior revenue outlook, investors expect limited growth for the future, posing a potential limit to the stock's rise.

Baxter's unappealing 2.9% ROE performance with significant debt use indicates increased business risk. High ROE, low debt companies are typically more qualitative.

Drugs used for weight loss like Ozempic pose a real risk to companies ranging from fast food restaurants to cigarette makers. Expect management teams of public companies to talk about them in their earnings calls.
Ozempic and Wegovy, two weight-loss medications, function by simulating the hormone that signals to people's brains when they are not hungry. Recent anecdotal data indicates that the medicine might reduce users' craving...

MACRO
Waller Says Fed 'Finally' Getting Good Inflation Data
"In the last few months, we are finally getting very good inflation data that we wanted." Federal Reserve Governor Christopher Waller says at the annual E2 Summit in Park City, Utah. "If this continues, we're back to our target."
U.S. Stocks Trade Mixed After Fed Minutes, Wholesale Inflation Data
U.S. stocks were trading mixed Wednesday afternoon after the Federal ...